Off-label prescribing of lower-dose direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) is associated with a higher risk of mortality, stroke and myocardial infarction (MI) and may not actually reduce bleeding risks, researchers have reported.